• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巨细胞动脉炎发病机制的新见解:维持血管炎症的相关机制

New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation.

作者信息

Greigert Hélène, Genet Coraline, Ramon André, Bonnotte Bernard, Samson Maxime

机构信息

Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, 14 Bd. Gaffarel, 21000 Dijon, France.

Department of Vascular Medicine, Dijon University Hospital, 14 Bd. Gaffarel, 21000 Dijon, France.

出版信息

J Clin Med. 2022 May 20;11(10):2905. doi: 10.3390/jcm11102905.

DOI:10.3390/jcm11102905
PMID:35629030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9143803/
Abstract

The giant cell arteritis (GCA) pathophysiology is complex and multifactorial, involving a predisposing genetic background, the role of immune aging and the activation of vascular dendritic cells by an unknown trigger. Once activated, dendritic cells recruit CD4 T cells and induce their activation, proliferation and polarization into Th1 and Th17, which produce interferon-gamma (IFN-γ) and interleukin-17 (IL-17), respectively. IFN-γ triggers the production of chemokines by vascular smooth muscle cells, which leads to the recruitment of additional CD4 and CD8 T cells and also monocytes that differentiate into macrophages. Recent data have shown that IL-17, IFN-γ and GM-CSF induce the differentiation of macrophage subpopulations, which play a role in the destruction of the arterial wall, in neoangiogenesis or intimal hyperplasia. Under the influence of different mediators, mainly endothelin-1 and PDGF, vascular smooth muscle cells migrate to the intima, proliferate and change their phenotype to become myofibroblasts that further proliferate and produce extracellular matrix proteins, increasing the vascular stenosis. In addition, several defects in the immune regulatory mechanisms probably contribute to chronic vascular inflammation in GCA: a defect in the PD-1/PD-L1 pathway, a quantitative and qualitative Treg deficiency, the implication of resident cells, the role of GM-CSF and IL-6, the implication of the NOTCH pathway and the role of mucosal-associated invariant T cells and tissue-resident memory T cells.

摘要

巨细胞动脉炎(GCA)的病理生理学复杂且多因素,涉及易感基因背景、免疫衰老的作用以及未知触发因素对血管树突状细胞的激活。一旦被激活,树突状细胞招募CD4 T细胞并诱导其激活、增殖以及向Th1和Th17极化,Th1和Th17分别产生干扰素-γ(IFN-γ)和白细胞介素-17(IL-17)。IFN-γ触发血管平滑肌细胞产生趋化因子,这导致额外的CD4和CD8 T细胞以及分化为巨噬细胞的单核细胞的募集。最近的数据表明,IL-17、IFN-γ和粒细胞-巨噬细胞集落刺激因子(GM-CSF)诱导巨噬细胞亚群的分化,这些亚群在动脉壁破坏、新生血管形成或内膜增生中起作用。在主要是内皮素-1和血小板衍生生长因子(PDGF)等不同介质的影响下,血管平滑肌细胞迁移至内膜,增殖并改变其表型成为肌成纤维细胞,后者进一步增殖并产生细胞外基质蛋白,加剧血管狭窄。此外,免疫调节机制中的一些缺陷可能导致GCA中的慢性血管炎症:PD-1/PD-L1途径缺陷、调节性T细胞(Treg)在数量和质量上的不足、驻留细胞的影响、GM-CSF和IL-6的作用、NOTCH途径的影响以及黏膜相关恒定T细胞和组织驻留记忆T细胞的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf70/9143803/d72fd8910966/jcm-11-02905-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf70/9143803/5e1d64224214/jcm-11-02905-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf70/9143803/c72d26579e5c/jcm-11-02905-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf70/9143803/d72fd8910966/jcm-11-02905-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf70/9143803/5e1d64224214/jcm-11-02905-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf70/9143803/c72d26579e5c/jcm-11-02905-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf70/9143803/d72fd8910966/jcm-11-02905-g003.jpg

相似文献

1
New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation.巨细胞动脉炎发病机制的新见解:维持血管炎症的相关机制
J Clin Med. 2022 May 20;11(10):2905. doi: 10.3390/jcm11102905.
2
[Epidemiology and pathophysiology of giant cell arteritis].[巨细胞动脉炎的流行病学与病理生理学]
Rev Prat. 2023 Apr;73(4):380-386.
3
Recent advances in our understanding of giant cell arteritis pathogenesis.巨细胞动脉炎发病机制研究的最新进展。
Autoimmun Rev. 2017 Aug;16(8):833-844. doi: 10.1016/j.autrev.2017.05.014. Epub 2017 May 28.
4
Neointimal myofibroblasts contribute to maintaining Th1/Tc1 and Th17/Tc17 inflammation in giant cell arteritis.新生内膜肌成纤维细胞有助于维持巨细胞动脉炎中的 Th1/Tc1 和 Th17/Tc17 炎症。
J Autoimmun. 2024 Jan;142:103151. doi: 10.1016/j.jaut.2023.103151. Epub 2023 Dec 1.
5
[Physiopathology of giant cell arteritis: From inflammation to vascular remodeling].[巨细胞动脉炎的病理生理学:从炎症到血管重塑]
Presse Med. 2019 Sep;48(9):919-930. doi: 10.1016/j.lpm.2019.07.031. Epub 2019 Sep 19.
6
Pathogenesis of giant cell arteritis: More than just an inflammatory condition?巨细胞动脉炎的发病机制:不仅仅是炎症性疾病?
Autoimmun Rev. 2010 Aug;9(10):635-45. doi: 10.1016/j.autrev.2010.05.002. Epub 2010 May 8.
7
Pathogenesis of giant cell arteritis: new insight into the implication of CD161+ T cells.巨细胞动脉炎的发病机制:CD161+T 细胞作用的新见解。
Clin Exp Rheumatol. 2013 Jan-Feb;31(1 Suppl 75):S65-73. Epub 2013 Apr 19.
8
Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis.内皮素-1 促进血管平滑肌细胞穿过血管壁迁移:一种导致巨细胞动脉炎血管重塑和内膜增生的机制。
Ann Rheum Dis. 2017 Sep;76(9):1624-1634. doi: 10.1136/annrheumdis-2016-210792. Epub 2017 Jun 12.
9
[Giant-cell arteritis pathogenesis].[巨细胞动脉炎的发病机制]
Presse Med. 2012 Oct;41(10):937-47. doi: 10.1016/j.lpm.2012.07.005. Epub 2012 Aug 14.
10
Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis.白细胞介素-21调节巨细胞动脉炎中的Th1和Th17反应。
Arthritis Rheum. 2012 Jun;64(6):2001-11. doi: 10.1002/art.34327. Epub 2011 Dec 6.

引用本文的文献

1
Efficacy and Safety of Biological Agents in Giant Cell Arteritis: An Updated Meta-Analysis.生物制剂治疗巨细胞动脉炎的疗效与安全性:一项更新的荟萃分析
Avicenna J Med. 2025 Jun 19;15(2):64-73. doi: 10.1055/s-0045-1809621. eCollection 2025 Apr.
2
Influence of socioeconomic status on access to temporal artery biopsy and rates of biopsy positivity in patients with suspected giant cell arteritis.社会经济地位对疑似巨细胞动脉炎患者颞动脉活检可及性及活检阳性率的影响。
BMC Rheumatol. 2025 May 14;9(1):52. doi: 10.1186/s41927-025-00503-0.
3
Distinct landscapes of fibroblast subtypes in arteries of patients with giant cell arteritis.

本文引用的文献

1
Treatment of Giant Cell Arteritis (GCA).巨细胞动脉炎(GCA)的治疗
J Clin Med. 2022 Mar 24;11(7):1799. doi: 10.3390/jcm11071799.
2
Cranial giant cell arteritis mimickers: A masquerade to unveil.颅 giant 细胞动脉炎的模仿者:揭开伪装。
Autoimmun Rev. 2022 May;21(5):103083. doi: 10.1016/j.autrev.2022.103083. Epub 2022 Mar 24.
3
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.马夫利昔单抗治疗巨细胞动脉炎的疗效和安全性:一项 2 期、随机、双盲、安慰剂对照试验。
巨细胞动脉炎患者动脉中不同的成纤维细胞亚型景观。
Rheumatology (Oxford). 2025 Jul 1;64(7):4382-4392. doi: 10.1093/rheumatology/keaf143.
4
CD6 in Human Disease.人类疾病中的CD6
Cells. 2025 Feb 13;14(4):272. doi: 10.3390/cells14040272.
5
Tissue degrading and remodelling molecules in giant cell arteritis.巨细胞动脉炎中的组织降解和重塑分子
Rheumatology (Oxford). 2025 May 1;64(5):3095-3103. doi: 10.1093/rheumatology/keae710.
6
Causal genes identification of giant cell arteritis in CD4+ Memory t cells: an integration of multi-omics and expression quantitative trait locus analysis.CD4+记忆T细胞中巨细胞动脉炎的致病基因鉴定:多组学与表达定量性状位点分析的整合
Inflamm Res. 2025 Jan 7;74(1):3. doi: 10.1007/s00011-024-01965-7.
7
The Set up and the Triggers: An Update on the Risk Factors for Giant Cell Arteritis.发病机制与触发因素:巨细胞动脉炎危险因素的最新进展
Curr Neurol Neurosci Rep. 2024 Dec 14;25(1):11. doi: 10.1007/s11910-024-01386-3.
8
Management of Coronary Artery Diseases in Systemic Vasculitides: Complications and Strategies.系统性血管炎相关冠状动脉疾病的管理:并发症与策略。
Medicina (Kaunas). 2024 Sep 25;60(10):1574. doi: 10.3390/medicina60101574.
9
mTOR signalling controls the formation of smooth muscle cell-derived luminal myofibroblasts during vasculitis.mTOR 信号通路控制血管炎时平滑肌细胞衍生的腔隙性肌成纤维细胞的形成。
EMBO Rep. 2024 Oct;25(10):4570-4593. doi: 10.1038/s44319-024-00251-1. Epub 2024 Sep 13.
10
Bing-Neel Syndrome: An Unknown GCA Mimicker.宾-尼尔综合征:一种未知的巨细胞动脉炎模仿者。
Case Rep Rheumatol. 2024 Aug 12;2024:2043012. doi: 10.1155/2024/2043012. eCollection 2024.
Ann Rheum Dis. 2022 May;81(5):653-661. doi: 10.1136/annrheumdis-2021-221865. Epub 2022 Mar 9.
4
Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study.巴利昔替尼治疗复发性巨细胞动脉炎:一项前瞻性开放标签 52 周的初步研究。
Ann Rheum Dis. 2022 Jun;81(6):861-867. doi: 10.1136/annrheumdis-2021-221961. Epub 2022 Feb 21.
5
Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis.用马伏鲁单抗阻断 GM-CSF 受体 α 可减少巨细胞动脉炎患者离体培养动脉中的浸润细胞、促炎标志物和新生血管形成。
Ann Rheum Dis. 2022 Apr;81(4):524-536. doi: 10.1136/annrheumdis-2021-220873. Epub 2022 Jan 19.
6
Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment.巨细胞动脉炎发病机制中功能异质性巨噬细胞亚群:疾病监测与治疗的新靶点
J Clin Med. 2021 Oct 26;10(21):4958. doi: 10.3390/jcm10214958.
7
Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis.作为巨细胞动脉炎治疗靶点的调节性 T 细胞功能障碍的新方面。
Ann Rheum Dis. 2022 Jan;81(1):124-131. doi: 10.1136/annrheumdis-2021-220955. Epub 2021 Sep 28.
8
Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis.托珠单抗治疗巨细胞动脉炎后调节性T细胞免疫反应的改善
Clin Transl Immunology. 2021 Sep 12;10(9):e1332. doi: 10.1002/cti2.1332. eCollection 2021.
9
Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial.司库奇尤单抗治疗巨细胞动脉炎的疗效和安全性:一项随机、平行分组、双盲、安慰剂对照的 II 期临床试验研究方案。
Trials. 2021 Aug 17;22(1):543. doi: 10.1186/s13063-021-05520-1.
10
Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica.CXCL9-CXCR3和CXCL13-CXCR5轴与巨细胞动脉炎和风湿性多肌痛中B细胞迁移的关联
J Autoimmun. 2021 Sep;123:102684. doi: 10.1016/j.jaut.2021.102684. Epub 2021 Jul 6.